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This document presents the conclusions of a detailed discussion on the role of topical NSAIDs during 
a round table Global Pain Faculty meeting held in Amsterdam in 2019 and subsequent discussions 
online. The aim of this evidence-based document is to describe the impact of musculoskeletal pain 
both in terms of the large numbers of sufferers and its economic impact. The document considers 
the place of topical therapies alongside other pharmacological and non-pharmacological treatments 
and presents the evidence for the benefits and harms of topical NSAIDS including indicators of 
efficacy for three main topical NSAIDs—diclofenac, ibuprofen and ketoprofen—based on almost 
15,000 participants in randomised controlled trials for acute and chronic musculoskeletal pain. These 
topical NSAIDs have the largest body of evidence. For acute pain, numbers needed to treat to  
achieve at least 50% reduction in pain are as follows with 95% confidence intervals in brackets: 
Diclofenac emulgel 1.8(1.5-2.1) (5170 participants), Ibuprofen gel 2.7 (1.7-4.2) (436 participants), 
Ketoprofen gel 2.2 (1.7-2.8) (683 participants). For chronic pain, the NNTs are Diclofenac any 
formulation 9.5(7-14) (5995 participants). Ketoprofen 6.9(5.5-9.3) (2573 participants). 
 
Randomised controlled trial evidence suggests that adverse events for active topical NSAIDs are 
similar to placebo. Finally the gaps in knowledge are considered with suggestions on how further 
research might help. The global pain faculty was brought together by GSK under an unrestricted 
educational grant.  
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We present the conclusions of a detailed discussion on the burden of musculoskeletal disease and 
the role of topical NSAIDs that took place during a round table Global Pain Faculty meeting held in 
Amsterdam in 2019 and subsequent discussions online. The Global Pain Faculty was organised by 
GSK under an unrestricted grant and the views expressed in this document are solely those of the 
authors. 
 
1. Musculoskeletal pain represents a substantial health problem,  
with an estimated 20–33% of people globally living with painful musculoskeletal conditions. 
The term musculoskeletal condition embraces a broad range of health conditions affecting bones, 
joints and muscles and rarer conditions of the immune system. This includes low back pain, 
osteoarthritis, neck pain, rheumatoid arthritis, gout and lupus. These disorders have multiple 
symptoms including pain, stiffness and a loss of mobility. They often interfere significantly with the 
normal daily activities of affected people. In the UK for instance, with a population of 70 million 
people, back pain alone is estimated to have an annual cost of  £1.6 billion in direct and £10 billion in 
indirect costs while treating osteoarthritis and rheumatoid arthritis (the two most common forms of 
arthritis) in 2017 is estimated to have cost another £10.2 billion[1]. 
Painful musculoskeletal conditions are common and affect large numbers of people worldwide. The 
most common painful musculoskeletal conditions are low back pain and osteoarthritis, estimated to 
affect more than 10 million and 8.5 million UK citizens, respectively. Estimates are available of the 
numbers affected from surveys undertaken at a local through to global level. For instance, in the UK 
in 2017 about 18.8 million people lived with a musculoskeletal disorder[2]. This represented about 
33% of females and 27% of males. The prevalence is age-related, with very few children suffering 
from these diseases, but more than 50% of those aged over 60 years.  
A large survey[3] of more than 46,000 individuals in 16 European countries examined the prevalence 
and causes of persistent pain. It asked how many people suffered from pain lasting at least 6 months 
and occurring several times per week and rated numerically as scoring at least 5 out of 10. Of the 
20% of the European population fulfilling these reasonably stringent criteria, 2/3 had 
musculoskeletal conditions, most commonly in the lower back. This survey was significant in that it 
also found that only a minority of people with persistent pain (34%) reported that medications 
offered adequate pain relief. Data from the 2009 National Health Interview Survey in America[4] 
found many individuals had suffered from musculoskeletal pain in a 3-month period: 28% pain in the 
lower back, 19% pain in the knee, 15% percent pain in the neck, and 8% pain in the hand.  
A recent cross-sectional survey [5] of more than 52,000 subjects in 14 countries (in Europe, the 
Middle East, Latin and Central America, North America and in Asia-Pacifica) assessed the global 
burden of musculoskeletal pain. It found that half of the population surveyed felt they had pain that 
had some substantial, multifaceted impact on their lives. 
These figures are representative of the burden on musculoskeletal pain in a wide range of 
countries.   
The prevalence of musculoskeletal conditions appears to have remained approximately stable over 
the last 30 years, highlighting the continuing medical need in this area.  
2. Musculoskeletal conditions are a leading cause of disability, being responsible for more than 
20% of all years lived with disability, and can profoundly impact quality-of-life as well as social 
and emotional well-being. 
One of the most respected methods for assessing the impact of particular medical disorders is the 











The main metric at the heart of the Global Burden of Disease project is health loss resulting either 
from premature death or from disability. It is calculated for a wide range of health conditions and 
expressed as the so-called ‘disability-adjusted life years’ (DALY). Since many health conditions are 
not associated with loss of life (and this generally includes musculoskeletal conditions), a second 
measure that is also useful is the ‘years lived with disability’ (YLD).  
The Global Burden of Disease survey in 2010 first identified that musculoskeletal pain conditions 
were amongst the leading causes of global disability and in 2016, low-back and neck pain were the 
third highest contributors to the total number of DALYs with only ischaemic heart disease and 
cerebrovascular disease contributing more on this measure. 
Low-back pain was the most common cause of YLD for men in 2016 and had the highest age 
standardized YLD rates in 133 of the 195 countries assessed.  In women, low-back pain similarly had 
the highest age-standardized YLD rates in 109 countries. 
Over the decade from 2006 to 2016, the number of estimated YLD for low-back/neck pain and for 
osteoarthritis rose by 19.3% and 31.5%, respectively. Most of this increase appeared to be driven by 
population increase.[1] Musculoskeletal conditions accounted for 18% of all YLD globally in 2017. 
3. Musculoskeletal pain is associated with a diverse range of societal consequences, and high 
economic costs reported to exceed those for heart disease, cancer and diabetes.  
Musculoskeletal ill health results in significant costs for individuals, employers, the health service, 
and the wider economy. It also has a significant impact on the quality of life of the individuals 
affected as well as their family and friends.  
 
The Pain in Europe survey found that pain sufferers (mostly with musculoskeletal conditions) had 
associated multiple adverse life experiences: 19% had lost a job because of their pain, 21% had been 
diagnosed with depression and over 40% reported feelings of helplessness or inability to think or 
function normally[3]. 
 
Musculoskeletal pain was recently reported to have significant negative effects on emotional 
wellbeing in 40%, and a significant adverse effect on quality of life in 59%, of a very large sample of 
individuals across 14 countries worldwide [5] 
 
In monetary terms, musculoskeletal illness has direct costs of medical care associated with treating 
the conditions and the indirect costs due to lower economic productivity associated with lost wages, 
disability days, and fewer hours worked. In the UK for instance, with a population of 70 million 
people, back pain alone is estimated to have an annual cost of  £1.6 billion in direct and £10 billion in 
indirect costs while treating osteoarthritis and rheumatoid arthritis (the two most common forms of 
arthritis) in 2017 is estimated to have cost another £10.2 billion[1].  
 
4. Management of musculoskeletal pain requires an integrated approach, utilising non-
pharmacological measures and pharmacological treatments which can include topical and/or 
systemic medications. 
For self-limiting conditions such as strains and sprains, topical or oral NSAIDs are usually         
effective. [6,7] [8] 
 
Systematic review evidence suggests that the initial steps in treating musculoskeletal pain related to 
osteoarthritis focus on non-pharmacological measures such as weight loss, exercise [9] and 












NSAIDs. [10]. Paracetamol has been shown to be of limited benefit in osteoarthritis [11]. Opioids 
have in general been discredited as they are often ineffective in chronic musculoskeletal pain and 
can induce dependency [12], [13]). For more severe conditions, intra-articular injections or joint 
surgery may be necessary[10]. 
 
Utilising non-pharmacological and pharmacological measures in an integrated way is advisable 
 
5. Topical administration of the NSAIDs diclofenac, ibuprofen and ketoprofen have been shown 
to provide effective relief of acute musculoskeletal pain. 
Robust evidence from systematic reviews exists for the effectiveness of topical NSAIDs including 
diclofenac (5170 participants), ibuprofen (436 participants),  and ketoprofen (683 participants) to 
provide pain relief for acute musculoskeletal pains such as sports injuries and other strains and 
sprains [6,8]. These topical NSAIDs have the largest body of evidence. We have defined effectiveness 
as a user reported reduction in pain intensity of at least 50% i.e. reducing pain by at least a half at 7 
days after starting treatment.  Numbers needed to treat (NNT) for the different NSAIDS when 
compared to a placebo using a similar base or vehicle were found to be as follows (presented with 
95% confidence intervals): 
 Diclofenac emulgel  1.8(1.5-2.1) 
 Diclofenac (any formulation) 4.2 (3.6-5.1) 
 Ibuprofen gel   2.7 (1.7-4.2) 
 Ketoprofen gel   2.2 (1.7-2.8) 
Taking diclofenac as an example the number needed to treat (NNT)  means that for every 1.8 (say 2) 
people treated with this product at least one will achieve a reduction in pain of at least a half that 
would not have been achieved by the application of placebo[8,14]. 
 
6. The topical NSAIDs diclofenac and ketoprofen can provide effective relief of chronic pain for 
some patients with knee or hand osteoarthritis; there is no high quality evidence for or 
against effectiveness in other chronic musculoskeletal pain conditions. 
Robust evidence from systematic reviews exists for the effectiveness of topical NSAIDs including 
diclofenac (5995 participants), and ketoprofen (2573 participants) to provide pain relief for chronic 
musculoskeletal pains such as knee or hand osteoarthritis [8,15]. We have defined effectiveness as a 
user reported reduction in pain intensity of at least 50% i.e. reducing pain by at least a half at 6-12 
weeks after starting treatment.  Numbers needed to treat for the different NSAIDS when compared 
to a placebo using a similar base or vehicles were found to be as follows (presented with 95% 
confidence intervals): 
 Diclofenac (any formulation) 9.5 (7-14) 
 Ketoprofen gel   6.9 (5.5-9.3) 
Taking diclofenac as an example the NNT means that for every 9 people treated with this product at 
least one will achieve a reduction in pain of at least a half that would not have been achieved by the 
application of placebo. While the NNT may be considered as relatively large (poor), if a patient 
benefits from a topical NSAID then they may not need to consider the use of other interventions 
with a worse adverse effect profile. 
 
Although studies in other osteoarthritis conditions were not identified in the systematic reviews, it 













7. In acute and chronic musculoskeletal pain trials, topical NSAIDs are well tolerated with 
minimal risk of systemic adverse events; application site reactions occur at a similar rate as for 
placebo and are generally mild and transient. 
Topical NSAIDs were developed to provide relief of musculoskeletal pain and eliminate or minimize 
the frequency of adverse events associated with oral or parenteral NSAIDs, which are sometimes 
severe and associated with mortality  
 
Three systematic reviews have described adverse events[8,14,15]. Adverse events in these studies 
are not the primary endpoint and they are not always well collected by trialists. In acute pain, 
administration of NSAIDs is short-term, rarely lasting more than two weeks. Also, topical applications 
of NSAIDs are applied as creams, gels, plasters, sprays or foams which may deliver different amounts 
of NSAIDs, and therefore the carrier may be important in both efficacy and adverse events 
associated with the active compounds. In the same way, these carriers were applied as placebo arms 
and their effect may also be different, especially in terms of potential adverse events.  
 
Reported local adverse events include irritation of the area of application described as reddens, 
erythema, itch, pruritus, and were usually mild and transient. The total number of participants 
included in the Cochrane meta-analysis for acute pain were 3619 with topical NSAIDs and 3121 with 
placebo [14].  The proportion of patients who reported a local adverse event was 4.3% with topical 
NSAIDs vs 4.6% with placebo (RR: 0.98 (95% CI 0.80 to 1.2). When NSAIDs were analysed individually, 
there were no differences with placebo, and the conclusion is that overall the frequency of local 
adverse events is very low with no difference between NSAIDs and placebo.  
 
Systemic adverse events were also infrequent with no differences between the topical NSAID and 
placebo (3.1% vs 3.5 with placebo (RR: 0.96; 95% CI 0.7-1.3). It was a similar story for withdrawals 
due to adverse events.  
 
In conclusion, the available literature confirms that topical NSAIDs do not show a higher incidence of 
local adverse events than the placebo carrier, and that it shows a lower incidence of systemic events 
compared to oral NSAIDs, although the incidence of serious adverse events is almost negligible in 
short-term treatments of acute musculoskeletal pain. 
 
Two reviews on chronic musculoskeletal pain[8,15] also reported adverse events with topical NSAIDs 
used up to 12 weeks. As in the acute pain review, most local adverse events included redness, 
erythema, and pruritic or dry skin. The higher number of days of application was associated with a 
higher frequency of local adverse events compared to acute pain studies  
 
Local adverse events with diclofenac were reported in 14% of patients vs.7.8% in patients treated 
with placebo carrier (RR: 1.8; 95% CI 1.5 to 2.2, NNH (number needed to harm) was 16; 95% CI: 12-
23) in the combined analysis of 15 studies available.  Ketoprofen was tested in four clinical trials, 
with local adverse rates of 15% vs 13% with placebo carrier (RR: 1.0; 95% CI: 0.85-1.3) [15].   
 
When topical application of NSAIDs was compared to oral NSAIDs, local adverse events were more 
frequent in patients with topical application of the NSAID (22% vs 5.8%), but the systemic events 
were more frequent in patients taking oral NSAIDs (17% vs 26%; RR for GI adverse events was 0.66 
(95% CI 0.56 to 0.77). More patients taking oral NSAIDs withdrew from the studies compared to 
topical NSAIDs due to adverse events.  In another systematic review oral NSAIDs in knee 














In conclusion, based on the evidence provided and compared to placebo, topical application of 
NSAIDs for longer periods of time in chronic pain was associated with similar or somewhat  higher 
local adverse events. Topical NSAIDs were also associated with less systemic adverse events than 
oral NSAIDs and absence of serious adverse events.  
 
8. Topical products other than NSAIDs are available; however, evidence for the efficacy of these 
products is negative for some and weak for others and their possible role in the management of 
musculoskeletal pain is undetermined. 
 
Topical products other than NSAIDs include products containing capsaicin, salicylates and menthol as 
well as Ayurvedic medicines and herbal medicines. However, there have been few well conducted 
studies to determine their effectiveness for musculoskeletal pain.  
 
A meta-analysis of studies of topical capsaicin in osteoarthritis included five randomised controlled 
trials and one case control cross over study using topical capsaicin formulations ranging in strength 
from 0.025 – 0.075% for period of 4-12 weeks[16] . Compared with placebo, capsaicin was 
associated with a modest reduction in a 10-point VAS score of 0.44 95% CI 0.25, 0.62); however, 35-
100% of patients reported mild application site burning associated with capsaicin (RR vs. placebo 
4.42 (95% CI 3.25, 5.48). Although generally mild, this burning sensation can be intolerable for some 
patients leading to treatment withdrawal in some patients in clinical studies [17,18] . 
 
Topical salicylate preparations, including methyl-salicylate, have shown some effects  in acute and 
chronic musculoskeletal pain and osteoarthritis; however, larger, more recent studies have failed to 
demonstrate a benefit of topical salicylates over placebo for musculoskeletal pain[19]. Based on 
limited evidence, the use of topical salicylates appears to be well tolerated.  However, potentiation 
of the anti-coagulant effect of warfarin by topical methyl-salicylate has been reported [20].  
 
9. Topical NSAIDs have a role in the management of mild-to-moderate musculoskeletal pain. 
 
NSAIDs are more effective than other pharmacological approaches in the management of pain 
associated with different musculoskeletal conditions. However, when used as oral treatment they 
may be associated with systemic (especially gastrointestinal, and less frequently cardiovascular) 
adverse events,  As a result, they are usually placed as the second or third step in the hierarchy or 
algorithms of management of pain associated with these conditions [21].  
Since the occurrence of adverse events with oral or parenteral NSAIDs is dose-dependent, another 
approach has been the use of topical NSAIDs. The aim of this approach is to deliver a high 
concentration of drug locally, while reducing systemic exposure to the drug and therefore 
decreasing the risk and frequency of adverse events.  The most recent systematic reviews and meta-
analysis reported in the previous statements have shown that topical administration of NSAIDs are 
more effective than placebo in the treatment of both acute and chronic musculoskeletal pain, have 













Based on these advantages, [22,23], most guidelines recommend now the use of topical NSAIDs 
(alone or combined with other measures) in the algorithms of pain treatment associated with 
musculoskeletal conditions, especially osteoarthritis.  
The recent 2018 update of the EULAR (The European League Against Rheumatism) 
recommendations for the management of hand OA indicate that topical treatments are preferred 
over systemic  treatments because of safety reasons and put topical NSAIDs as the treatment of 
choice within this category [21] Also, the 2018  Asia-Pacific expert consensus on the use of topical 
NSAIDs in musculoskeletal pain points out that they should be recommended as a first-line 
intervention for mild to moderate pain and that they have comparable efficacy to oral NSAIDs [24] . 
The American College of Rheumatology recommended the use of topical NSAIDs in the management 
of hand and knee OA at the same level than oral NSAIDs or other pharmacological treatments, but 
no recommendations were made for topical  NSAIDs for patients with hip OA due to the lack of data 
from RCTs [25] The more recent guidelines published by the Osteoarthritis Research Society 
International (OARSI) strongly recommends the use of topical NSAIDs in the treatments of knee OA, 
whereas the use of oral NSAIDs is conditional based on the presence of either  GI or CV 
comorbidities [26]. 
Similar recommendations are given by other societies such as the European Society for Clinical and 
Economic aspects of osteoporosis and osteoarthritis (ESCEO), where topical NSAIDS are placed on 
the top of the algorithm in the management of knee OA after the use of symptomatic slow acting 
drugs for osteoarthritis and short-term paracetamol rescue analgesia [23]. 
In summary, topical application of NSAIDs is considered as treatment of choice among the 
pharmacological approaches in patients with musculoskeletal pain. Guidelines of different scientific 
societies strongly recommend the use of topical NSAIDs on the top and first step of any 
pharmacological treatment in the management of knee and hand osteoarthritis.  
 
10. Studies are needed to establish the best use of topical NSAIDs in the management of acute 
and chronic musculoskeletal pain, including: Agent, formulation and dose of topical NSAIDS. 
 
As reviewed above, there is clear and robust evidence for analgesic efficacy of topical NSAIDs in 
some acute and chronic musculoskeletal conditions. However, there are many questions about the 
use of topical NSAIDs that are currently not well answered. Some of these are: What is the best type 
of NSAID?; best dose?; best formulation? What conditions are ideally treated by topical NSAIDs?  
 
The relative lack of head to head comparison studies partly underlies this uncertainty. But another 
reason is that there are limited published mechanistic studies of the effects of topical NSIADs. Of 
course, there is a good understanding of how NSAIDs in general produce analgesia but the spatial 
and pharmacodynamic distribution of different NSAIDs in different formulations and at different 
concentrations is not widely available. These data would be of considerable value in understanding 
and comparing different formulations of agents. It would also provide a rationale for topical NSAIDs 
use in different conditions. It might also facilitate a wider exploration of the potential benefits of 
topical NSAIDs. One example is low back pain. This is an extremely common form of musculoskeletal 
pain (see above) but is not generally considered as a target for topical NSAID treatment at the 













The systematic reviews failed to identify any clinical trials comparing one topical NSAID with 
another. There does seem to be a difference in the effectiveness of different formulations and needs 
to be investigated further. Finally the role of topical NSAIDs in chronic pain needs wider exploration 
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